Close Menu

New York (GenomeWeb)  GenomicVision announced today that it has extended its collaboration and commercialization agreement with Quest Diagnostics for the development of new biomarkers to improve the genetic detection of spinal muscular atrophy.

The companies are accelerating the pace of their collaboration with the goal of detecting SMA "2+0" carrier status. Identification of this rare form of mutation would lead to greater sensitivity in SMA screening, according to Genomic Vision.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.